{"doi":"10.1056/nejmoa1507643","title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer","abstract":"<h4>Background</h4>Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.<h4>Methods</h4>In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival.<h4>Results</h4>Overall survival was longer with nivolumab than with docetaxel. The median overall survival was 12.2 months (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 months (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0.59 to 0.89; P=0.002). At 1 year, the overall survival rate was 51% (95% CI, 45 to 56) with nivolumab versus 39% (95% CI, 33 to 45) with docetaxel. With additional follow-up, the overall survival rate at 18 months was 39% (95% CI, 34 to 45) with nivolumab versus 23% (95% CI, 19 to 28) with docetaxel. The response rate was 19% with nivolumab versus 12% with docetaxel (P=0.02). Although progression-free survival did not favor nivolumab over docetaxel (median, 2.3 months and 4.2 months, respectively), the rate of progression-free survival at 1 year was higher with nivolumab than with docetaxel (19% and 8%, respectively). Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1%, ≥5%, and ≥10%) of the PD-1 ligand. Treatment-related adverse events of grade 3 or 4 were reported in 10% of the patients in the nivolumab group, as compared with 54% of those in the docetaxel group.<h4>Conclusions</h4>Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).","journal":"New England Journal of Medicine","year":2015,"id":190,"datarank":16.342177747655697,"base_score":9.150059441091253,"endowment":9.150059441091253,"self_citation_contribution":1.372508916163688,"citation_network_contribution":14.969668831492008,"self_endowment_contribution":1.372508916163688,"citer_contribution":14.969668831492008,"corpus_percentile":92.5,"corpus_rank":1190,"citation_count":9414,"citer_count":156,"citers_with_citation_signal":156,"citers_with_endowment":156,"datacite_reuse_total":0,"is_dataset":false,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2015-10-22","authors":[{"id":1537,"name":"Luis Paz-Ares","orcid":null,"position":1,"is_corresponding":false},{"id":74876,"name":"Diane P Holder","orcid":null,"position":2,"is_corresponding":false},{"id":1539,"name":"David R. Spigel","orcid":"0000-0003-3215-9465","position":3,"is_corresponding":false},{"id":1540,"name":"Martin Steins","orcid":null,"position":4,"is_corresponding":false},{"id":1541,"name":"Neal E. Ready","orcid":null,"position":5,"is_corresponding":false},{"id":1542,"name":"Laura Q. Chow","orcid":null,"position":6,"is_corresponding":false},{"id":1543,"name":"Everett E. Vokes","orcid":"0000-0002-8645-8068","position":7,"is_corresponding":false},{"id":1544,"name":"Enriqueta Felip","orcid":"0000-0002-7620-0098","position":8,"is_corresponding":false},{"id":1545,"name":"Esther Holgado","orcid":"0000-0002-7008-7135","position":9,"is_corresponding":false},{"id":1546,"name":"Fabrice Barlesi","orcid":null,"position":10,"is_corresponding":false},{"id":1547,"name":"Martin Kohlhäufl","orcid":null,"position":11,"is_corresponding":false},{"id":1548,"name":"Oscar Arrieta","orcid":null,"position":12,"is_corresponding":false},{"id":1549,"name":"Marco Angelo Burgio","orcid":null,"position":13,"is_corresponding":false},{"id":1550,"name":"Jérôme Fayette","orcid":"0000-0002-8126-7019","position":14,"is_corresponding":false},{"id":1551,"name":"Hervé Lena","orcid":null,"position":15,"is_corresponding":false},{"id":1552,"name":"Elena Poddubskaya","orcid":"0000-0001-6476-6337","position":16,"is_corresponding":false},{"id":1553,"name":"David E. Gerber","orcid":"0000-0002-7812-6741","position":17,"is_corresponding":false},{"id":1554,"name":"Scott N. Gettinger","orcid":null,"position":18,"is_corresponding":false},{"id":1555,"name":"Charles M. Rudin","orcid":"0000-0001-5204-3465","position":19,"is_corresponding":false},{"id":1556,"name":"Naiyer Rizvi","orcid":null,"position":20,"is_corresponding":false},{"id":1557,"name":"Lucio Crinò","orcid":"0000-0001-5745-6429","position":21,"is_corresponding":false},{"id":1558,"name":"George R. Blumenschein","orcid":"0000-0002-9606-8194","position":22,"is_corresponding":false},{"id":1559,"name":"Scott J. Antonia","orcid":null,"position":23,"is_corresponding":false},{"id":1560,"name":"Cécile Dorange","orcid":null,"position":24,"is_corresponding":false},{"id":1561,"name":"Christopher T. Harbison","orcid":null,"position":25,"is_corresponding":false},{"id":1562,"name":"Friedrich Graf Finckenstein","orcid":null,"position":26,"is_corresponding":false},{"id":1563,"name":"Julie R. Brahmer","orcid":"0000-0002-2443-8395","position":27,"is_corresponding":false},{"id":1564,"name":"H. Borghaei","orcid":null,"position":28,"is_corresponding":false},{"id":1565,"name":"L. Paz-Ares","orcid":null,"position":29,"is_corresponding":false},{"id":1566,"name":"Neal Ready","orcid":"0000-0003-4414-9432","position":30,"is_corresponding":false},{"id":1567,"name":"Laura Q.M. Chow","orcid":"0000-0002-7237-017X","position":31,"is_corresponding":false},{"id":1568,"name":"Fabrice Barlési","orcid":"0000-0001-5793-3539","position":32,"is_corresponding":false},{"id":1569,"name":"M. Kohlhufl","orcid":null,"position":33,"is_corresponding":false},{"id":1570,"name":"Óscar Arrieta","orcid":"0000-0002-1164-3779","position":34,"is_corresponding":false},{"id":1571,"name":"M. Burgio","orcid":null,"position":35,"is_corresponding":false},{"id":1572,"name":"H. Lena","orcid":null,"position":36,"is_corresponding":false},{"id":1573,"name":"Scott Gettinger","orcid":"0000-0003-0886-6880","position":37,"is_corresponding":false},{"id":1574,"name":"Naiyer A. Rizvi","orcid":"0000-0002-1134-7494","position":38,"is_corresponding":false},{"id":1575,"name":"L. Crina","orcid":null,"position":39,"is_corresponding":false},{"id":1576,"name":"Scott Antonia","orcid":"0000-0002-6686-3824","position":40,"is_corresponding":false},{"id":1577,"name":"Christopher Harbison","orcid":null,"position":41,"is_corresponding":false},{"id":1578,"name":"F. Graf Finckenstein","orcid":null,"position":42,"is_corresponding":false},{"id":1536,"name":"Hossein Borghaei","orcid":null,"position":0,"is_corresponding":true}],"reference_count":19,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-03-01T18:20:47.508186Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}